These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

903 related items for PubMed ID: 30713280

  • 1. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T.
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [Abstract] [Full Text] [Related]

  • 2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, Hasegawa S, Okuyama Y, Ogino N, Yamauchi H, Kobashi Y, Yamazoe S, Munetomo Y, Mogami T, Nomura T.
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [Abstract] [Full Text] [Related]

  • 3. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
    Takaoka K, Kishimoto H.
    Nihon Yakurigaku Zasshi; 2019 May; 153(1):22-27. PubMed ID: 30643088
    [Abstract] [Full Text] [Related]

  • 4. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ, Steybe D, Poxleitner P, Schmelzeisen R, Munzenmayer C, Fuellgraf H, Stricker A, Semper-Hogg W.
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, Zillikens MC, Body JJ.
    J Clin Endocrinol Metab; 2022 Apr 19; 107(5):1441-1460. PubMed ID: 34922381
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Update MRONJ and perspectives of its treatment.
    Voss PJ, Poxleitner P, Schmelzeisen R, Stricker A, Semper-Hogg W.
    J Stomatol Oral Maxillofac Surg; 2017 Sep 19; 118(4):232-235. PubMed ID: 28697987
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
    Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S.
    J Bone Miner Metab; 2017 Jan 19; 35(1):6-19. PubMed ID: 28035494
    [Abstract] [Full Text] [Related]

  • 20. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G, Manfredi M, Giovannacci I, Mergoni G, Sarraj A, Mureddu M, Giunta G, Bonanini M, Meleti M, Vescovi P.
    Minerva Stomatol; 2017 Aug 19; 66(4):135-140. PubMed ID: 28497661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.